ALBERTA BLUE CROSS®

ADALIMUMAB / VEDOLIZUMAB for Crohn's / INFLIXIMAB for Crohn's / Fistulizing Crohn's Disease
SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta government-sponsored drug programs.

PATIENT INFORMATION				COVERAGE TYPE
PATIENT LAST NAME	FIRST NAME	INITIAL		☐ Alberta Blue Cross ☐ Alberta Human Services ☐ Other
BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER			
STREET ADDRESS	CITY	PROV	POSTAL CODE	ID, CLIENT OR COVERAGE NUMBER

PRESCRIBER INFORMATION			
PRESCRIBER LAST NAME	FIRST NAME	INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION ☐ CPSA ☐ ACO ☐ CARNA ☐ ADA+C ☐ ACP ☐ Other REGISTRATION NUMBER
STREET ADDRESS			
CITY, PROVINCE			PHONE / FAX
POSTAL CODE			FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED

Please provide the following information for ALL requests

Diagnosis
- ☐ Moderately to Severely Active Crohn's (MSAC)
- ☐ Fistulizing Crohn's
- ☐ Other (please specify) _____

Indicate requested drug
- ☐ Entyvio
- ☐ [1]Inflectra
- ☐ [1]Renflexis
- ☐ Humira
- ☐ [1]Remicade

1. See p. 2 for Biosimilar Switch Policy

Current weight (kg)

Dosage and frequency

Date of last dose

For INITIAL requests, please indicate if the drug is requested for a
- ☐ NEW patient who has never been treated with the requested drug by any health care provider.
- ☐ EXISTING patient who is being treated or has previously been treated with the requested drug.
  → Please provide the treatment start date _____

Please provide reason if a switch to a different biologic agent or change in dose is requested.

Note: Patients will not be permitted to switch back to a previously trialed biologic agent if they were deemed unresponsive to therapy

Infliximab for Fistulizing Crohn's Disease

INITIAL requests

Dose, duration and response are required for all medications previously utilized.

Azathioprine

6-mercaptopurine

Antibiotic(s) (specify drug name)

NEW patient

Does the patient have actively draining perianal or enterocutaneous fistula(s) that have recurred or persisted despite previous therapy?

☐ Yes ☐ No

EXISTING patient

Please indicate response to treatment with Infliximab

- ☐ Closure of individual fistulas as evidenced by no or minimal fistula drainage despite gentle finger compression of fistulas that were draining at baseline.
- ☐ Incomplete response (please specify) _____
- ☐ Loss of response to 5mg/kg dosing: increase to 10mg/kg required

Adalimumab, Infliximab or Vedolizumab for MSAC

INITIAL requests

Dose, duration and response are required for all medications previously utilized, or contraindications, if applicable

Azathioprine

6-mercaptopurine

Methotrexate

Mesalamine

Glucocorticoid(s) (specify drug name)

ALL requests

Modified Harvey-Bradshaw Index score _____

Date of score _____

For Infliximab requests for an increase to 10mg/kg dosing

1) Is the patient already maintained on Infliximab 10 mg/kg?

☐ Yes ☐ No

2) Confirm the patient had an incomplete response to Infliximab 5mg/kg dosing

☐ Yes ☐ No (explain) _____

3) Most recent Modified Harvey-Bradshaw Index score from when the patient was *responding* to 5mg/kg dosing _____ Date_____

Additional information relating to request

PRESCRIBER'S SIGNATURE	DATE (YYYY-MM-DD)	Please forward this request to
		Alberta Blue Cross, Clinical Drug Services **10009 108 Street NW, Edmonton, Alberta T5J 3C5** **FAX 780-498-8384** in Edmonton • **1-877-828-4106** toll free all other areas

ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST

ALBERTA BLUE CROSS®

ADALIMUMAB / VEDOLIZUMAB for Crohn's / INFLIXIMAB for Crohn's / Fistulizing Crohn's Disease
SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta government-sponsored drug programs.

1. Biosimilar Switch Policy

As of December 12, 2019, adult (18 years of age and older) patients using an originator biologic for which there is a biosimilar treatment option for their indication and who wish to maintain Alberta Health coverage of the molecule will be required to switch to the biosimilar by January 15, 2021. During the transition period from December 12, 2019 to January 14, 2021, Alberta Health will cover both the originator biologic and the biosimilar(s) of the affected drug(s). Effective January 15, 2021, Alberta Health will only cover the biosimilar versions of the drugs listed below, for the affected indications.

Drug	Originator (Switch from)	Biosimilar (Switch to)	Indication
Infliximab	Remicade	Inflectra or Renflexis	Crohn's Disease

For Biosimilar Initiative Exception Requests

Please complete the Biosimilar Initiative / Tiering Exception Special Authorization Request Form.